Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07258836 · ClinicalTrials.gov registry record · Phase 1
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
A Phase 1 study of Healthy and Neoplasms, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 5
- Study locations
NCT07258836 is a Phase 1 study of Healthy and Neoplasms that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 41 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT07258836, a Phase 1 study of Healthy and Neoplasms, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Interventions
- DRUG LY4214835
Study Locations (5)
Massachusetts
- Boston Medical Center - Boston
- Massachusetts General Hospital (MGH) - Charlestown
Connecticut
- Invicro - New Haven
Michigan
- BAMF Health Inc. - Grand Rapids
New York
- Ichor Research - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2025-12-22 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07258836
The ClinicalTrials.gov registry entry for NCT07258836 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which LY4214835 is the first listed.
NCT07258836 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Connecticut, Michigan.
Frequently Asked Questions
What is clinical trial NCT07258836 about?
NCT07258836 is a clinical study titled "A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer". The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
What is the current status of trial NCT07258836?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2025-12-22. Estimated completion is 2027-01.
What conditions does trial NCT07258836 study?
This clinical trial studies the following conditions: Healthy, Neoplasms.
What interventions are being tested in trial NCT07258836?
The interventions under investigation include: LY4214835 (DRUG).
Who is sponsoring clinical trial NCT07258836?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07258836 being conducted?
This trial has 5 study locations across Connecticut, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.